See the DrugPatentWatch profile for Azstarys
The comparison between Azstarys and Jornay PM reveals key differences in their formulations, mechanisms of action, and potential applications for treating Attention Deficit Hyperactivity Disorder (ADHD).
How do Azstarys and Jornay PM work differently?
Azstarys is a once-daily oral medication that contains two active ingredients: serdexymethylphenidate (SDX) and dexmethylphenidate. SDX is a prodrug that is converted in the body to dexmethylphenidate. This dual-release mechanism allows for an immediate dose of dexmethylphenidate and a delayed release from the SDX conversion, aiming for a smooth plasma concentration profile [1].
Jornay PM also offers a delayed-release formulation, but it contains only dexmethylphenidate. It is designed with a unique capsule that has a special coating. This coating delays the release of the medication until it passes through the stomach and reaches the small intestine, where it is then absorbed [2]. This delayed release is intended to provide therapeutic effects in the morning and maintain them throughout the day.
What are the approved uses for Azstarys and Jornay PM?
Azstarys is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients six years of age and older [1].
Jornay PM is also indicated for the treatment of ADHD in patients six years of age and older [2].
What are the ingredients in Azstarys?
Azstarys contains serdexmethylphenidate and dexmethylphenidate [1]. Serdexmethylphenidate is a prodrug, meaning it is converted into dexmethylphenidate within the body. This conversion process contributes to the drug's dual-release mechanism.
What are the ingredients in Jornay PM?
Jornay PM contains dexmethylphenidate as its sole active ingredient [2]. The medication's delivery system is designed to control the release of dexmethylphenidate throughout the day.
When do the patents for these ADHD medications expire?
Information regarding specific patent expiry dates for Azstarys and Jornay PM is proprietary. However, DrugPatentWatch.com tracks patent information for pharmaceutical products. Generally, patent protection for branded medications is a critical factor in the availability of generic alternatives. New drug formulations and delivery systems can extend market exclusivity beyond the initial patent life of the active ingredient [3].
How do these medications compare in terms of side effects?
Common side effects reported for Azstarys include decreased appetite, insomnia, weight loss, and nausea [1].
Common side effects for Jornay PM include insomnia, decreased appetite, headache, and nausea [2].
Both medications, as central nervous system stimulants, carry a risk of serious cardiovascular events, psychiatric effects, and potential for abuse and dependence.
What is the difference in how Azstarys and Jornay PM are taken?
Azstarys is taken once daily, with or without food [1].
Jornay PM is also taken once daily, but it is specifically designed to be taken in the evening before bedtime [2]. This evening dosing allows the medication to be released and absorbed in the morning.
Can these medications be used for adults with ADHD?
Azstarys is indicated for ADHD in patients six years of age and older [1].
Jornay PM is indicated for ADHD in patients six years of age and older [2].
What is the mechanism of action for Azstarys and Jornay PM?
Both Azstarys and Jornay PM are central nervous system (CNS) stimulants. The active ingredient, dexmethylphenidate, works by increasing the levels of certain neurotransmitters, primarily dopamine and norepinephrine, in the brain. These neurotransmitters play a role in attention, focus, and impulse control. Azstarys has a dual-release mechanism due to its serdexmethylphenidate prodrug component, while Jornay PM utilizes a delayed-release capsule formulation [1, 2].
---
1. Azstarys Prescribing Information
2. Jornay PM Prescribing Information
3. DrugPatentWatch.com